---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029619"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:06:27.071600+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IDEAYA Enters Clinical Collaboration with Merck to Evaluate IDE161 + KEYTRUDA in Endometrial Cancer

## Summary
- Phase 1 trial will test IDE161 (PARG inhibitor) + KEYTRUDA in MSI-high and MSS endometrial cancer.
- Merck provides KEYTRUDA at no cost; IDEAYA sponsors the trial and pays study costs.
- Each party retains full commercial rights to its own compound as monotherapy or combination.
- IDE161 has FDA Fast-Track designation for BRCA1/2 ovarian and breast cancers.

## SEC filing metadata
- accession: 0000950170-24-029619
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017024029619/0000950170-24-029619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017024029619/idya-20240308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029619
- JSON: https://secwatch.observer/filing/0000950170-24-029619.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.